265 related articles for article (PubMed ID: 33904240)
1. Targeting SARS-CoV-2 Spike Protein/ACE2 Protein-Protein Interactions: a Computational Study.
Pirolli D; Righino B; De Rosa MC
Mol Inform; 2021 Jun; 40(6):e2060080. PubMed ID: 33904240
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV- 2 Infection (COVID-19).
Nayak SK
Mini Rev Med Chem; 2021; 21(6):689-703. PubMed ID: 33208074
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of ACE2-Spike Interaction by an ACE2 Binder Suppresses SARS-CoV-2 Entry.
Shin YH; Jeong K; Lee J; Lee HJ; Yim J; Kim J; Kim S; Park SB
Angew Chem Int Ed Engl; 2022 Mar; 61(11):e202115695. PubMed ID: 35043545
[TBL] [Abstract][Full Text] [Related]
4. Withanone from
Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
[TBL] [Abstract][Full Text] [Related]
5. Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions.
Day CJ; Bailly B; Guillon P; Dirr L; Jen FE; Spillings BL; Mak J; von Itzstein M; Haselhorst T; Jennings MP
mBio; 2021 Mar; 12(2):. PubMed ID: 33785634
[TBL] [Abstract][Full Text] [Related]
6. Molecular screening of glycyrrhizin-based inhibitors against ACE2 host receptor of SARS-CoV-2.
Ahmad S; Waheed Y; Abro A; Abbasi SW; Ismail S
J Mol Model; 2021 Jun; 27(7):206. PubMed ID: 34169390
[TBL] [Abstract][Full Text] [Related]
7. Tinocordiside from
Balkrishna A; Pokhrel S; Varshney A
Comb Chem High Throughput Screen; 2021; 24(10):1795-1802. PubMed ID: 33172372
[TBL] [Abstract][Full Text] [Related]
8. Contributions of human ACE2 and TMPRSS2 in determining host-pathogen interaction of COVID-19.
Senapati S; Banerjee P; Bhagavatula S; Kushwaha PP; Kumar S
J Genet; 2021; 100(1):. PubMed ID: 33707363
[TBL] [Abstract][Full Text] [Related]
9. Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries.
David AB; Diamant E; Dor E; Barnea A; Natan N; Levin L; Chapman S; Mimran LC; Epstein E; Zichel R; Torgeman A
Molecules; 2021 May; 26(11):. PubMed ID: 34072087
[TBL] [Abstract][Full Text] [Related]
10. Identification of potential SARS-CoV-2 entry inhibitors by targeting the interface region between the spike RBD and human ACE2.
Gurung AB; Ali MA; Lee J; Farah MA; Al-Anazi KM
J Infect Public Health; 2021 Feb; 14(2):227-237. PubMed ID: 33493919
[TBL] [Abstract][Full Text] [Related]
11. Detection of Binding Sites on SARS-CoV-2 Spike Protein Receptor-Binding Domain by Molecular Dynamics Simulations in Mixed Solvents.
Jokinen EM; Gopinath K; Kurkinen ST; Pentikainen OT
IEEE/ACM Trans Comput Biol Bioinform; 2021; 18(4):1281-1289. PubMed ID: 33914685
[TBL] [Abstract][Full Text] [Related]
12. Screened antipsychotic drugs inhibit SARS-CoV-2 binding with ACE2 in vitro.
Lu J; Hou Y; Ge S; Wang X; Wang J; Hu T; Lv Y; He H; Wang C
Life Sci; 2021 Feb; 266():118889. PubMed ID: 33310043
[TBL] [Abstract][Full Text] [Related]
13. Shedding Light on the Inhibitory Mechanisms of SARS-CoV-1/CoV-2 Spike Proteins by ACE2-Designed Peptides.
Freitas FC; Ferreira PHB; Favaro DC; Oliveira RJ
J Chem Inf Model; 2021 Mar; 61(3):1226-1243. PubMed ID: 33619962
[TBL] [Abstract][Full Text] [Related]
14. Active components in Ephedra sinica stapf disrupt the interaction between ACE2 and SARS-CoV-2 RBD: Potent COVID-19 therapeutic agents.
Mei J; Zhou Y; Yang X; Zhang F; Liu X; Yu B
J Ethnopharmacol; 2021 Oct; 278():114303. PubMed ID: 34102269
[TBL] [Abstract][Full Text] [Related]
15. Neutralizing Aptamers Block S/RBD-ACE2 Interactions and Prevent Host Cell Infection.
Liu X; Wang YL; Wu J; Qi J; Zeng Z; Wan Q; Chen Z; Manandhar P; Cavener VS; Boyle NR; Fu X; Salazar E; Kuchipudi SV; Kapur V; Zhang X; Umetani M; Sen M; Willson RC; Chen SH; Zu Y
Angew Chem Int Ed Engl; 2021 Apr; 60(18):10273-10278. PubMed ID: 33684258
[TBL] [Abstract][Full Text] [Related]
16. Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2).
Xiang Y; Wang M; Chen H; Chen L
Biochem Pharmacol; 2021 Oct; 192():114724. PubMed ID: 34371003
[TBL] [Abstract][Full Text] [Related]
17. Corilagin prevents SARS-CoV-2 infection by targeting RBD-ACE2 binding.
Yang LJ; Chen RH; Hamdoun S; Coghi P; Ng JPL; Zhang DW; Guo X; Xia C; Law BYK; Wong VKW
Phytomedicine; 2021 Jul; 87():153591. PubMed ID: 34029937
[TBL] [Abstract][Full Text] [Related]
18. The chaperone GRP78 is a host auxiliary factor for SARS-CoV-2 and GRP78 depleting antibody blocks viral entry and infection.
Carlos AJ; Ha DP; Yeh DW; Van Krieken R; Tseng CC; Zhang P; Gill P; Machida K; Lee AS
J Biol Chem; 2021; 296():100759. PubMed ID: 33965375
[TBL] [Abstract][Full Text] [Related]
19. Targeting the viral-entry facilitators of SARS-CoV-2 as a therapeutic strategy in COVID-19.
Muralidar S; Gopal G; Visaga Ambi S
J Med Virol; 2021 Sep; 93(9):5260-5276. PubMed ID: 33851732
[TBL] [Abstract][Full Text] [Related]
20. Common cardiac medications potently inhibit ACE2 binding to the SARS-CoV-2 Spike, and block virus penetration and infectivity in human lung cells.
Caohuy H; Eidelman O; Chen T; Liu S; Yang Q; Bera A; Walton NI; Wang TT; Pollard HB
Sci Rep; 2021 Nov; 11(1):22195. PubMed ID: 34773067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]